Lubeluzole treatment of acute ischemic stroke

Stroke

Volumn 28, Issue 12, 1997, Pages 2338-2346

  Grotta, James ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Clinical trials; Efficacy; Ischemic stroke; Lubeluzole; Neuroprotection; Safety

Indexed keywords

LUBELUZOLE; PLACEBO;

ADULT; AGED; ARTICLE; BRADYCARDIA; BRAIN ISCHEMIA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; FEVER; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROPROTECTION; PAIN; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; URINARY TRACT INFECTION; VOMITING;

EID: 0031438509     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.28.12.2338     Document Type: Article

References (14)

1. De Ryck M, Keersmaeckers R, Duytschaever H, Claes C, Clincke G, Janssen M, Vanreet G. Lubeluzole protects sensorimotor function and reduces infarct size in a photochemical stroke model in rats. J Pharmacol Exp Ther. 1996;279:748-758.
2. Aronowski J, Strong R, Grotta JC. Treatment of experimental focal ischemia in rats with lubeluzole. Neuropharmacology 1996;35:689-693.
3. Scheller D, Kolb J, Szathmary S, Zacharias E, de Ryck M, van Reempts J, Clincke G, Tegtmeier F. Extracellular changes of glutamate in the periinfarct zone: effect of lubeluzole. J Cereb Blood Flow Metab. 1995;15(suppl 1):S379. Abstract.
4. Buchkremer-Ratzmann I, Witte OW. Periinfarct and transhemispheric diaschisis caused by photothrombotic infarction in rat neocortex is reduced by lubeluzole but not MK-801. J Cereb Blood Flow Metab. 1995;15(suppl 1):S38. Abstract.
5. Lesage AS, Peelers L, Leysen JF. Lubeluzole, a novel long-term neuroprotectant, inhibits the glutamate-activated nitric oxide synthethase pathway. J Pharmacol Exp Ther. 1996;279:759-766.
6. Maiese K, Tenbroeke M, Kue I. Neuroprotection of lubeluzole is mediated through the signal transduction pathways of nitric oxide. J Neurochem. 1997;68:710-714.
7. Diener HC, Hacke W, Hennerici M, Rådberg J, Hantson L, De Keyser J, for the Lubeluzole International Study Group. Lubeluzole in acute ischemic stroke: a double-blind, placebo-controlled phase II trial. Stroke. 1996;27:76-81.
8. Hacke W, Hennerici H, Hantson L, Diener HC. Lubeluzole: a new neuroprotectant agent in the treatment of acute ischemic stroke. Results of a cardiovascular safety study in stroke patients. Neurology. 1996;46:A429. Abstract.
9. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh E, and the TOAST Investigators. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. Stroke. 1993;24:35-41.
10. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V, Rovick M, Moomaw C, Walker M. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864-870.
11. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J. 1965;14:61-65.
12. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604-607.
13. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemie stroke. N Engl J Med. 1995;333:1581-1587.
14. De Ryck M. Protection of neurologic function in stroke models and neuroprotective properties of lubeluzole. Cerebrovasc Dis. 1997; 7(suppl 2):18-30.